A Phase 3 interventional study of Different post-operative antibiotic regimens following surgical treatment of mandible fractures in Mandible Fracture and Post-operative Antibiotics, sponsored by East Lancashire Hospitals NHS Trust. Recruiting at 2 sites in United Kingdom. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-01-22.
Sponsored by East Lancashire Hospitals NHS Trust · Phase 3, Interventional, and Treatment
Aim: To determine whether post-operative antibiotics are required at all, following surgery for mandible fractures, and, if so, what is the most clinically- and cost-effective regimen
Objectives:
Primary Objective To conduct a Randomized Controlled Trial (MANTRA) in order to establish the non-inferiority (or not) of not giving post-operative antibiotics versus 2 other post-operative antibiotic regimens. An internal pilot phase will optimise recruitment and retention.
Secondary Objectives
The participants will be randomised to the following (1:1:1):
Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).
Trial processes will be optimised by an internal pilot phase ensuring we recruit, randomise, and retain participants with clear progression criteria. We will also conduct cost-effectiveness analyses and process evaluation for dissemination and implementation
Timeline:
Start of grant: 1st July 2023 Start of RCT / pilot: 1st January 2024 End of pilot: 30th June 2024 End of recruitment: 31st December 2026 End of follow-up: 30th June 2027 Completion: 31st December 2027
Impact and dissemination:
All adult patients aged 18 years or over with mandible fractures requiring surgery. Most of these patients will be identified from the A\&E department via the on-call OMFS team or seen in dedicated OMFS trauma clinics. A small proportion of our study population will be seen in an OMFS clinic following referral from GP/GDP.
Inclusion Criteria:
Exclusion Criteria:
Group A: One induction IV dose
Drug: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
Group B: One induction IV dose and 2 further postoperative IV doses
Drug: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
Group C: One IV dose of antibiotics on induction and 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy
Drug: Different post-operative antibiotic regimens following surgical treatment of mandible fractures
The 3 study arms represent the most common antibiotic regimens used in current clinical practice following surgery for mandible fractures. The control group is the most common approach. All patients will receive 1 dose of IV antibiotics (co-amoxiclav 1.2g), if no penicillin allergy, on induction of anaesthesia, prior to their surgery. The participants will be randomised to the following (1:1:1): Group A: No further antibiotics Group B: 2 further postoperative IV doses of co-amoxiclav 1.2g Group C: 2 further postoperative IV doses (as above), followed by a 5-day course of oral co-amoxiclav 625mg every 8 hours if no penicillin allergy (Control).
Surgical Site Infection
Incidence of Surgical Site Infection (CDC definition) following surgery for mandible fractures
Time frame: 30 days
Return to theatre within 30 days
Time frame: 30 days
Length of hospital stay
Time frame: 14 days, 30 days, 180 days
Death and cause of death
Time frame: 14 days, 30 days, 180 days
Hospital readmission
Time frame: 30 days
Malunion: fracture non-healing
Fibrous union, fracture mobility, absence of callus formation
Time frame: 180 days
Malocclusion: teeth not meeting as they should
When the fracture reduction failed to restore the dental occlusion
Time frame: 180 days
Metalwork removal
When the fixation titanium miniplates need to be removed at any point and for any reason
Time frame: 14 days, 30 days, 180 days
Overall antibiotic exposure
Time frame: 14 days, 30 days, 180 days
Antibiotic related adverse events/serious adverse events
Time frame: 14 days, 30 days, 180 days
Cost
Time frame: 14 days, 30 days, 180 days
HRQoL (EQ-5D-5L)
Health Related Quality of Life
Time frame: 14 days, 30 days, 180 days
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
East Lancashire Hospitals NHS Trust